Risk-Adjusted Value Modeling (rNPV)
The defensible asset valuation tool.
A practical guide to risk-adjusted NPV (rNPV) in pharma — assumptions, structure, common errors and decision use.
"What is the asset really worth, on a risk-adjusted basis?"
rNPV is the standard for pharma asset valuation. Done well, it surfaces value drivers and risk exposures. Done badly, it produces overconfident point estimates that mislead.
rNPV is the de facto standard for pharma asset valuation. The valuation that survives IC committee scrutiny is one with explicit PoS, asset-class WACC, sensitivity tornado, and a defensible range — not a point estimate.
What we’re seeing in the data.
Phase-by-phase PoS is the spine
Most rNPVs fail because PoS isn’t TA-specific.
Discount rate often misapplied
Different rates for different risk classes.
Range > point estimate
Always communicate as a defensible range.
Sensitivity dominates conviction
Conviction comes from understanding what moves the answer.
How to think about it.
-
01
Build cash flow forecast
Volume × price × LoE × geo.
-
02
Apply phase-specific PoS
TA-, sponsor-, modality-adjusted.
-
03
Discount appropriately
Asset-class WACC.
-
04
Run sensitivities
Tornado chart of drivers.
-
05
Communicate as range
Defensible band, never point.
What separates a good answer from a defensible one.
FX volatility on multi-decade flows.
Materially affects NPV.
Often understated.
Combination dependencies link asset NPVs.
Where the signal comes from.
Common questions.
Should we use industry-average PoS in rNPV?
No — TA × phase × modality × sponsor adjusted. Industry average misleads.
Is rNPV enough for IC?
Necessary, not sufficient. Combine with strategic fit, capability and capacity scoring.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist